1. Home
  2. FGBI vs PYXS Comparison

FGBI vs PYXS Comparison

Compare FGBI & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Guaranty Bancshares Inc.

FGBI

First Guaranty Bancshares Inc.

HOLD

Current Price

$8.84

Market Cap

134.1M

Sector

Finance

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$3.39

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGBI
PYXS
Founded
1934
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.1M
141.3M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
FGBI
PYXS
Price
$8.84
$3.39
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
14.0K
848.7K
Earning Date
04-27-2026
05-13-2026
Dividend Yield
0.44%
N/A
EPS Growth
N/A
3.03
EPS
0.31
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
$567.70
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
$28.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.31
$1.03
52 Week High
$11.02
$5.55

Technical Indicators

Market Signals
Indicator
FGBI
PYXS
Relative Strength Index (RSI) 53.82 52.01
Support Level $8.24 $2.95
Resistance Level $8.86 $3.45
Average True Range (ATR) 0.28 0.32
MACD 0.09 -0.03
Stochastic Oscillator 93.20 29.86

Price Performance

Historical Comparison
FGBI
PYXS

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: